Levetiracetam

English name levetiracetam

also known as LEV · Keppra · AGB101 · LVT · (S)-α-ethyl-2-oxo-pyrrolidine acetamide · eLVT · Keppra (Registered Trademark) · Keppra, Levetiracetam · +8 more

Other / unclassified targets SV2A

Developed for: epilepsy · focal epilepsy · epilepsy with generalized tonic-clonic seizures · Alzheimer disease · schizophrenia · neonatal epilepsy syndrome · Parkinson disease · traumatic brain injury
+59 more
· cognitive impairment with or without cerebellar ataxia · alcohol dependence · epilepsy syndrome · generalized epilepsy · post-traumatic epilepsy · stroke disorder · alcohol abuse · brain hypoxia - ischemia · cardiac arrest · cerebral malaria · cocaine dependence · cognitive disorder · intracerebral hemorrhage · self-limited epilepsy with centrotemporal spikes · social phobia · tardive dyskinesia · alcohol-related disorders · Alzheimer disease 3 · aphasia · benign non-familial infantile seizures · bipolar disorder · body dysmorphic disorder · brain neoplasm · childhood absence epilepsy · chronic idiopathic neuropathy · craniofacial dystonia · developmental and/or epileptic encephalopathy with spike-wave activation in sleep · drug-induced mental disorder · essential tremor · fibromyalgia · generalized anxiety disorder · glioblastoma · infectious disease with sepsis · lateral sclerosis · middle cerebral artery infarction · migraine disorder · multiple sclerosis · neuropathy, painful · oromandibular dystonia · panic disorder · photosensitive epilepsy · postherpetic neuralgia · premenstrual dysphoric disorder · progressive muscular atrophy · psychotic disorder · restless legs syndrome · schizoaffective disorder · schizophreniform disorder · severe pre-eclampsia · status asthmaticus · Tourette syndrome · alcohol withdrawal · bipolar depression · brain glioma · drug-induced dyskinesia · glioma · obsessive-compulsive disorder · post-traumatic stress disorder · subarachnoid hemorrhage
Investigated by: UCB Pharma · UCB Japan Co. Ltd. · Johns Hopkins University · AgeneBio · National Institute of Neurological Disorders and Stroke (NINDS) · National Institute on Aging (NIA)
+167 more
· Teva Pharmaceuticals USA · Yale University · Assistance Publique - Hôpitaux de Paris · Odense University Hospital · Auckland City Hospital · Children's Hospital Medical Center, Cincinnati · Ministry of Health, Italy · National Institutes of Health (NIH) · RESnTEC, Institute of Research · Rady Children's Hospital, San Diego · Rennes University Hospital · Richard H. Haas · Sohag University · University of California, San Diego · University of California, San Francisco · University of Minnesota · University of Rochester · University of Twente · Vanderbilt University Medical Center · Academic Medical Center - University of Amsterdam · Ache Laboratorios Farmaceuticos S.A. · All India Institute of Medical Sciences, Jodhpur · Amiens University Hospital · Assiut University · Ayal A. Aizer, MD · Azienda Ospedaliera San Gerardo di Monza · Banaras Hindu University · Beijing Tiantan Hospital · Belgium Health Care Knowledge Centre · Berkshire Health Systems · Beth Israel Deaconess Medical Center · Boston Medical Center · Boston University · Brigham and Women's Hospital · Butler Hospital · Cambridge University Hospitals NHS Foundation Trust · Canisius-Wilhelmina Hospital · Children's Hospital of Fudan University · Cleveland Clinic Lou Ruvo Center for Brain Health · Clinical Trial Unit, University Hospital Basel, Switzerland · Dana-Farber Cancer Institute · Dr. Reddy's Laboratories Limited · Drexel University College of Medicine · Duke University · Dutch Epilepsy Clinics Foundation · Erasme University Hospital · Food and Drug Administration (FDA) · French National Institute of Health and Medical Research · Fundación CITA Alzheimer · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · GlaxoSmithKline · Gomal Medical College · Guangzhou Women and Children's Medical Center · Hamilton Health Sciences Corporation · Hannover Medical School · Harvey S. Singer · Hayat Abad Medical Complex, Peshawar · Hospices Civils de Lyon · Hospital Universitario Marqués de Valdecilla · IRCCS National Neurological Institute "C. Mondino" Foundation · Indian Council of Medical Research · Institute of Medical Sciences of the Banaras Hindu University, India · Kessler Foundation · King's College London · Loyola University · Ludwig-Maximilians - University of Munich · Maasstad Hospital · Maastricht University Medical Center · Manipal Academy for Higher Education · Mario Negri Institute for Pharmacological Research · Massachusetts General Hospital · Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region · Maternal and Child Health Hospital of Hubei Province · Mazandaran University of Medical Sciences · all 173 on the full record

Regulatory milestones approvals, filings & regulatory actions · 14 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed epilepsy, early-onset 1 milestone
Filed	Japan (PMDA)	E Keppra	epilepsy, early-onset	2014-08-04	“filed an application for partial changes in marketing authorization of E Keppra for IV Drip Infusion 500 mg (levetiracetam) in Japan” otsuka.co.jp ↗
Approved Indication not stated 5 milestones
Label expansions (2)	US (FDA)	SPRITAM	—	2021-01-19 – 2025-06-27	fda.gov ↗
Label expansions (8)	US (FDA)	KEPPRA	—	2005-06-21 – 2019-10-23	fda.gov ↗
Label expansion	US (FDA)	KEPPRA XR	—	2014-08-01	fda.gov ↗
Approved	EU (EMA)	Keppra	—	2000-09-29	europa.eu ↗
Approved	US (FDA)	KEPPRA	—	1999-11-30	fda.gov ↗

Trials 169 · started per year

today

US approved 1999

EU approved 2000

1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 112 trials · 3 met primary
Phase 1	NCT03695094	Sep 2018 → May 2019	epilepsy	UCB Biopharma S.P.R.L.	Completed	No outcome recorded
Phase 1	NCT02602860	Nov 2015 → Sep 2017	—	UCB Pharma	Completed	No outcome recorded
Phase 1	NCT01725009	Oct → Dec 2012	—	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 1	NCT01618877	May → Jul 2012	—	UCB Pharma	Completed	No outcome recorded
Phase 1	NCT01521130	Jan 2012 → Jul 2017	self-limited epilepsy with centrotemporal spikes	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1	NCT00859521	Jan 2007	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00859430	Jan 2007	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00849485	Nov 2005	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00849862	Oct → Nov 2005	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00227461	Sep 2005 → Dec 2021	aphasia, stroke disorder	Kessler Foundation	Unknown	No outcome recorded
Phase 1	NCT00946751	Mar 2004	epilepsy	Sandoz	Completed	No outcome recorded
Phase 1	NCT01131897	Sep 2003	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded

Phase 1/27 trials
Phase 1/2	NCT03034356	Sep 2018 → Jun 2024	schizophrenia	VA Office of Research and Development	Completed	No outcome recorded
Phase 1/2	NCT02550028	Sep 2015 → Jan 2017	neonatal epilepsy syndrome	Children's Hospital of Fudan University	Terminated	No outcome recorded
Phase 1/2	NCT01720667	Mar 2013 → Oct 2017	neonatal epilepsy syndrome	Richard H. Haas	Completed	No outcome recorded
Phase 1/2	NCT01660672	Jan → Jul 2013	cerebral malaria, epilepsy	University of Rochester	Completed	No outcome recorded
Phase 1/2	NCT01239212	Sep 2010 → Jul 2011	epilepsy	Children's Hospital Medical Center, Cincinnati	Completed	No outcome recorded
Phase 1/2	NCT00884052	Apr 2007 → Mar 2011	epilepsy	Richard H. Haas	Completed	No outcome recorded
Phase 1/2	NCT00620165	Jan 2005 → Mar 2008	essential tremor	Southern California Institute for Research and Education	Completed	No outcome recorded
Phase 247 trials · 3 met primary · 2 missed
Phase 2	NCT07130786	Dec 2025 → Feb 2029 expected	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma, primary motor cortex epilepsy	Ayal A. Aizer, MD	Recruiting	No outcome recorded
Phase 2	NCT07477431	Oct 2025 → Jan 2027 expected	Alzheimer disease	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
Phase 2	NCT06919926	Apr 2025 → May 2027 expected	dementia	Johns Hopkins University	Active not recruiting	No outcome recorded
Phase 2	NCT05986721	Dec 2024 → Jul 2028	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	AgeneBio	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT05824728	Sep 2023 → Dec 2026 expected	Parkinson disease	Johns Hopkins University	Active not recruiting	No outcome recorded
Phase 2	NCT05610085	Mar 2023 → Jul 2027 expected	brain hypoxia - ischemia, neonatal epilepsy syndrome	University of California, San Diego	Recruiting	No outcome recorded
Phase 2	NCT04926844	Jun 2021 → Aug 2022	epilepsy with generalized tonic-clonic seizures	Sohag University	Completed	No outcome recorded
Phase 2	NCT04643327	Feb 2021 → Jan 2025 overdue	Parkinson disease, cognitive disorder, cognitive impairment with or without cerebellar ataxia	The University of Queensland	Recruiting	No outcome recorded
Phase 2	NCT04559529	Sep 2020 → Dec 2023	schizophrenia	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 2	NCT04277936	May → Aug 2020	schizophrenia	Vanderbilt University Medical Center	Terminated	No outcome recorded
Phase 2	NCT04004702	Jan 2020 → Dec 2024	Alzheimer disease	Walter Reed National Military Medical Center	Unknown	No outcome recorded
Phase 2	NCT03875638	Aug 2019 → Feb 2026	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 2	NCT03461861	Apr 2019 → Mar 2021	Alzheimer disease 4	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT03489044	Oct 2018 → Mar 2022	Alzheimer disease, epilepsy	University of Oxford	Completed	No outcome recorded
Phase 2	NCT02229123	Feb 2018 → Feb 2022	neonatal epilepsy syndrome	University Hospital, Tours	Completed	No outcome recorded
Phase 2	NCT03129360	Aug 2017 → Nov 2021	schizoaffective disorder, schizophrenia, schizophreniform disorder	NYU Langone Health	Completed	No outcome recorded
Phase 2	NCT02815410	Jul 2016 → Jun 2019	glioblastoma	Seoul National University Hospital	Unknown	Met primary
Phase 2	NCT02920060	Jan 2015 → Jul 2016	epilepsy with generalized tonic-clonic seizures	Banaras Hindu University	Completed	No outcome recorded
Phase 2	NCT02002819	Oct 2014 → Jul 2020	Alzheimer disease	University of Minnesota	Completed	Missed primary
Phase 2	NCT02199509	Jul 2014 → Mar 2016	craniofacial dystonia, oromandibular dystonia	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	No outcome recorded
Phase 2	NCT01982812	Jan 2014 → Jun 2015	cerebral malaria, epilepsy	University of Rochester	Completed	No outcome recorded
Phase 2	NCT01407523	Jul 2011 → Feb 2012	focal epilepsy	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 2	NCT01044758	Dec 2009 → Jul 2012	cognitive disorder	Johns Hopkins University	Completed	No outcome recorded
Phase 2	NCT00961441	Sep 2009 → Mar 2010	epilepsy	UCB BIOSCIENCES, Inc.	Completed	No outcome recorded
Phase 2	NCT00862563	May 2009 → Aug 2013	alcohol abuse, alcohol dependence	Boston Medical Center	Terminated	Met primary Stop: Enrollment
Phase 2	NCT00894010	May 2009 → Jun 2011	photosensitive epilepsy	The Epilepsy Study Consortium	Completed	No outcome recorded
Phase 2	NCT00505934	May 2008 → Mar 2010	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00627133	Feb 2008	alcohol-related disorders	Medical University of South Carolina	Withdrawn	No outcome recorded
Phase 2	NCT00603135	Jan 2008 → Jul 2009	epilepsy syndrome	University Hospital, Basel, Switzerland	Withdrawn	No outcome recorded
Phase 2	NCT00535392	Sep 2007 → Feb 2010	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00577005	Jul 2007 → Jun 2008	cocaine dependence, opiate dependence	Yale University	Completed	Missed primary
Phase 2	NCT00593125	Jan → Aug 2007	cocaine dependence, opiate dependence	Yale University	Completed	No outcome recorded
Phase 2	NCT00362141	Oct 2006 → Apr 2008	status asthmaticus	Medical Center Haaglanden	Unknown	No outcome recorded
Phase 2	NCT00324454	May 2006 → Dec 2007	lateral sclerosis, progressive muscular atrophy	Duke University	Completed	No outcome recorded
Phase 2	NCT00156689	Aug 2005 → May 2007	chronic idiopathic neuropathy	Vanderbilt University	Completed	No outcome recorded
Phase 2	NCT00175955	May → Dec 2005	tardive dyskinesia	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00105040	Sep 2004 → Mar 2007	focal epilepsy	UCB Pharma	Completed	Met primary
Phase 2	NCT00610454	Jun → Aug 2004	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00160511	Apr 2004 → Aug 2005	postherpetic neuralgia	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00141115	Mar 2004 → Jan 2008	alcohol dependence, generalized anxiety disorder, panic disorder, social phobia	New York State Psychiatric Institute	Completed	No outcome recorded
Phase 2	NCT00247364	Nov 2003 → Oct 2005	restless legs syndrome	Sleep Health Centers	Completed	No outcome recorded
Phase 2	NCT00612859	Sep 2003 → Jun 2004	social phobia	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00160576	Jul 2003 → Nov 2004	Parkinson disease	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00544050	Sep 2002 → May 2003	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00015769	Apr 2001 → Apr 2003	bipolar disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 2	NCT00600509	Jan 2001 → Jul 2003	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 2	NCT00545012	May 2000 → May 2003	epilepsy syndrome	UCB Pharma	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT07046611	Jul 2025 → Jun 2026 overdue	epilepsy with generalized tonic-clonic seizures	Sohag University	Recruiting	No outcome recorded
Phase 2/3	NCT03486938	Dec 2018 → Nov 2022	Alzheimer disease, cognitive impairment with or without cerebellar ataxia	AgeneBio	Completed	No outcome recorded
Phase 2/3	NCT00465244	Jan 2008 → May 2010	epilepsy	Massachusetts General Hospital	Withdrawn	No outcome recorded Stop: Enrollment
Phase 344 trials · 9 met primary · 5 missed
Phase 3	NCT07239115	May 2026 → Jan 2027 expected	post-traumatic epilepsy	Beijing Tiantan Hospital	Recruiting	No outcome recorded
Phase 3	NCT07220902	Jan 2026 → Dec 2033 expected	severe pre-eclampsia	Nebraska Methodist Health System	Not yet recruiting	No outcome recorded
Phase 3	NCT07234695	Dec 2025 → Dec 2027 expected	Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology, epilepsy, trisomy 21	Sant Pau Research Institute	Recruiting	No outcome recorded
Phase 3	NCT06773364	Apr 2025 → Dec 2028 expected	stroke disorder	Shanghai East Hospital	Recruiting	No outcome recorded
Phase 3	NCT06851078	Mar 2025 → Jun 2027 expected	infectious disease with sepsis	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 3	NCT05897658	Mar 2025 → Mar 2026 overdue	brain neoplasm, epilepsy	Hamilton Health Sciences Corporation	Not yet recruiting	No outcome recorded
Phase 3	NCT06442748	Jul 2024 → Jun 2031 expected	epilepsy, primary brain neoplasm	Tata Memorial Centre	Recruiting	No outcome recorded
Phase 3	NCT04573803	Mar 2021 → Mar 2026 overdue	post-traumatic epilepsy, traumatic brain injury	Cambridge University Hospitals NHS Foundation Trust	Not yet recruiting	No outcome recorded
Phase 3	NCT03340064	Nov 2017 → Jun 2021	focal epilepsy	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 3	NCT02631759	Oct 2016 → Apr 2021	intracerebral hemorrhage	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 3	NCT02374567	Jan 2015 → Jun 2017	anxiety disorder, dementia, depressive disorder, schizophrenia +1	Hannover Medical School	Terminated	No outcome recorded
Phase 3	NCT01954121	Sep 2013 → Sep 2015	focal epilepsy	UCB Pharma	Completed	Missed primary
Phase 3	NCT01392768	Jan 2013 → Jul 2015	focal epilepsy	Ache Laboratorios Farmaceuticos S.A.	Completed	No outcome recorded
Phase 3	NCT01506882	Dec 2011 → Oct 2013	focal epilepsy	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 3	NCT01345058	Aug 2011 → Feb 2014	epilepsy	Brigham and Women's Hospital	Completed	Missed primary
Phase 3	NCT01398956	Jun 2011 → Apr 2016	epilepsy with generalized tonic-clonic seizures	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT01292837	Feb 2011 → Jun 2013	epilepsy with generalized tonic-clonic seizures	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 3	NCT01228747	Oct 2010 → Apr 2014	epilepsy with generalized tonic-clonic seizures	UCB Japan Co. Ltd.	Completed	Met primary
Phase 3	NCT01063764	Jan 2010 → Apr 2011	epilepsy	UCB Japan Co. Ltd.	Completed	Met primary
Phase 3	NCT01150331	Jul 2009 → May 2013	epilepsy with generalized tonic-clonic seizures	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 3	NCT00419393	Dec 2007 → Mar 2010	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00566046	Nov 2007 → Dec 2009	post-traumatic epilepsy	Rennes University Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00542802	Sep 2007 → Jun 2009	epilepsy, stroke disorder	Scienze Neurologiche Ospedaliere	Unknown	No outcome recorded
Phase 3	NCT00376766	Feb 2007 → Apr 2008	epilepsy	University Hospital, Grenoble	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00368069	Aug 2006 → May 2007	epilepsy	UCB Pharma	Completed	Met primary
Phase 3	NCT00367432	Jul 2006 → Dec 2010	epilepsy	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 3	NCT00471744	Jun 2006 → Jul 2008	self-limited epilepsy with centrotemporal spikes	Ludwig-Maximilians - University of Munich	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00291655	Jun 2006 → Apr 2008	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00280696	Nov 2005 → Nov 2007	focal epilepsy	UCB Japan Co. Ltd.	Completed	Missed primary
Phase 3	NCT00150813	Aug 2005 → May 2007	epilepsy with generalized tonic-clonic seizures	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00175903	Feb 2005 → Oct 2007	epilepsy	UCB Pharma	Completed	Missed primary
Phase 3	NCT00152516	Oct 2004 → Jun 2008	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00175890	Oct 2004 → Jan 2007	focal epilepsy	UCB Pharma	Completed	Met primary
Phase 3	NCT00152373	Jul 2004 → May 2005	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00160628	Mar → Oct 2004	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00150787	Jul 2003 → Nov 2005	epilepsy with generalized tonic-clonic seizures	UCB Pharma	Completed	Met primary
Phase 3	NCT00150735	Jun 2002 → Jul 2005	generalized epilepsy	UCB Pharma	Completed	Met primary
Phase 3	NCT00150774	Nov 2001 → Dec 2004	generalized epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00150748	Nov 2001 → Jul 2007	generalized epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00160615	Sep 2001 → Jan 2007	focal epilepsy	UCB Japan Co. Ltd.	Completed	No outcome recorded
Phase 3	NCT00160550	Sep 2001 → Jun 2005	epilepsy with generalized tonic-clonic seizures	UCB Pharma	Completed	Met primary
Phase 3	NCT00615615	Sep 1999 → Mar 2003	epilepsy	UCB Pharma	Completed	Met primary
Phase 3	NCT00150709	Jan 1998 → Jan 2006	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 3	NCT00291213	? → Apr 2006	tardive dyskinesia	Yale University	Completed	Met primary

Phase 435 trials · 1 met primary · 1 missed
Phase 4	NCT07072624	Jul 2025 → Mar 2027 expected	epilepsy, traumatic brain injury	All India Institute of Medical Sciences, Jodhpur	Recruiting	No outcome recorded
Phase 4	NCT06866691	Apr 2025 → Apr 2027 expected	traumatic brain injury	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 4	NCT06081283	Nov 2023 → Dec 2024	brain hypoxia - ischemia, cardiac arrest, intracerebral hemorrhage, traumatic brain injury	University of North Carolina, Chapel Hill	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT07422233	Sep 2023 → Dec 2025	epilepsy	Nasim Tabrizi	Completed	No outcome recorded
Phase 4	NCT05969054	Jul 2023 → Dec 2025	Alzheimer disease 3, epilepsy	Xiangya Hospital of Central South University	Unknown	No outcome recorded
Phase 4	NCT03689114	May 2021 → Jun 2024	focal epilepsy	Mario Negri Institute for Pharmacological Research	Completed	No outcome recorded
Phase 4	NCT04176887	Jan 2019 → Feb 2020	—	Tanta University	Unknown	No outcome recorded
Phase 4	NCT03940326	Apr 2018 → Oct 2019	epilepsy with generalized tonic-clonic seizures	Mazandaran University of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT03054285	Jul 2017 → Apr 2020	epilepsy, traumatic brain injury	Loyola University	Unknown	No outcome recorded
Phase 4	NCT02334722	Aug 2015 → Oct 2020	brain cancer, epilepsy	University of Florida	Completed	No outcome recorded
Phase 4	NCT02429596	May 2012 → May 2015	epilepsy	IRCCS National Neurological Institute "C. Mondino" Foundation	Unknown	No outcome recorded
Phase 4	NCT01491113	Nov 2011 → Nov 2012	impaired renal function disease	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT02208492	Sep 2011 → Dec 2013	focal epilepsy	Yonsei University	Completed	No outcome recorded
Phase 4	NCT01498822	Jun 2011 → Jul 2014	epilepsy	UCB Pharma	Completed	Met primary
Phase 4	NCT01229735	Nov 2010 → May 2015	epilepsy	UCB Pharma	Completed	Missed primary
Phase 4	NCT00571155	Dec 2007 → Aug 2009	epilepsy, primary brain neoplasm	University Hospital Tuebingen	Completed	No outcome recorded
Phase 4	NCT00584025	Dec 2007 → Jun 2008	Parkinson disease	University of South Florida	Withdrawn	No outcome recorded
Phase 4	NCT00393614	May 2007 → Mar 2010	developmental and/or epileptic encephalopathy with spike-wave activation in sleep	Oslo University Hospital	Unknown	No outcome recorded
Phase 4	NCT00855738	May 2007 → Jun 2009	focal epilepsy	Viatris Inc.	Completed	No outcome recorded
Phase 4	NCT00370838	Feb 2007 → Jul 2008	Tourette syndrome	Harvey S. Singer	Completed	No outcome recorded
Phase 4	NCT00423527	Jan 2007 → Jan 2009	multiple sclerosis	Odense University Hospital	Completed	No outcome recorded
Phase 4	NCT01318408	Nov 2006 → Mar 2008	epilepsy	Drexel University College of Medicine	Completed	No outcome recorded
Phase 4	NCT00307450	Mar 2006 → Mar 2009	Parkinson disease	Technical University Dresden	Completed	No outcome recorded
Phase 4	NCT00286260	Jan 2006 → Aug 2008	neuropathy, painful	Odense University Hospital	Completed	No outcome recorded
Phase 4	NCT00325182	Jan 2006 → Jan 2007	alcohol dependence	Boston University	Completed	No outcome recorded
Phase 4	NCT00181116	Mar 2005 → Sep 2006	epilepsy	Johns Hopkins University	Completed	No outcome recorded
Phase 4	NCT00223223	Feb → Nov 2005	drug-induced mental disorder	University of Texas Southwestern Medical Center	Completed	No outcome recorded
Phase 4	NCT00265109	Dec 2004 → Jan 2008	body dysmorphic disorder	Butler Hospital	Completed	No outcome recorded
Phase 4	NCT00160654	Nov 2003 → Dec 2006	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT00630357	Mar 2003 → Jul 2004	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT00245713	Mar 2003 → Nov 2004	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT00631150	Mar 2003 → Jul 2004	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT00630630	Nov 2002 → Nov 2003	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT00643500	Jan 2002 → May 2003	focal epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 4	NCT00630968	Aug 2000 → Feb 2004	epilepsy	UCB Pharma	Completed	No outcome recorded

Phase not applicable21 trials · 3 missed
—	NCT06549426	Apr 2025 → Dec 2029 expected	epilepsy	University of Twente	Recruiting	No outcome recorded
—	NCT07163572	Jan → Aug 2025	—	Muhammad Aamir Latif	Completed	No outcome recorded
—	NCT07052136	Nov 2024 → Apr 2025	—	RESnTEC, Institute of Research	Completed	No outcome recorded
—	NCT07163585	Aug 2024 → Jul 2025	epilepsy	RESnTEC, Institute of Research	Completed	No outcome recorded
—	NCT06224530	Jul 2024 → Feb 2026 overdue	psychotic disorder	King's College London	Recruiting	No outcome recorded
—	NCT07401433	Apr 2024 → Mar 2025	neonatal epilepsy syndrome	Hayat Abad Medical Complex, Peshawar	Completed	Missed primary
—	NCT05860153	Jun 2023 → Jan 2024	benign non-familial infantile seizures	Assiut University	Unknown	No outcome recorded
—	NCT04939675	Jul 2021 → Jun 2023	epilepsy	National Taiwan University Hospital	Unknown	No outcome recorded
—	NCT04858841	Aug 2020 → Jul 2023	middle cerebral artery infarction	National Cheng Kung University	Unknown	No outcome recorded
—	NCT05236166	Apr 2017 → May 2021	epilepsy	University Magna Graecia	Completed	No outcome recorded
—	NCT02056236	Apr 2014 → Apr 2021	cardiac arrest	University of Twente	Completed	Missed primary
—	NCT02647437	Jun 2013 → Sep 2024	schizophrenia	University of Colorado, Denver	Completed	No outcome recorded
—	NCT01168687	Nov 2008 → Nov 2009	alcohol abuse	University of California, San Francisco	Completed	Missed primary
—	NCT00415376	Feb → Jul 2007	cancer of unknown primary site, central nervous system neoplasm, epilepsy	Northwestern University	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00361010	Dec 2006 → Dec 2007	childhood absence epilepsy	The Cleveland Clinic	Completed	No outcome recorded
—	NCT00254657	Mar 2004 → Mar 2005	fibromyalgia	University of California, San Francisco	Completed	No outcome recorded
—	NCT00262262	Mar 2004 → Sep 2006	—	Odense University Hospital	Completed	No outcome recorded
—	NCT00221988	Mar 2004 → Oct 2007	epilepsy	University Hospitals Cleveland Medical Center	Completed	No outcome recorded
—	NCT00518570	Nov 2003 → Oct 2006	premenstrual dysphoric disorder	Berkshire Health Systems	Completed	No outcome recorded
—	NCT00208520	Jul 2003 → Jun 2007	epilepsy syndrome	Dutch Epilepsy Clinics Foundation	Unknown	No outcome recorded
—	NCT00203216	Sep 2002 → Jan 2005	migraine disorder	Thomas Jefferson University	Completed	No outcome recorded

Comparator or background therapy60 trials
Phase 1	NCT02707965 Comparator	Jun 2017 → Aug 2018	epilepsy	Food and Drug Administration (FDA)	Completed	No outcome recorded
Phase 1	NCT00736931 Comparator	Jul → Oct 2008	epilepsy	UCB Pharma	Completed	No outcome recorded
Phase 1/2	NCT04833907 Background	Apr 2021 → Aug 2026 overdue	Canavan disease	Myrtelle Inc.	Enrolling by invitation	No outcome recorded
Phase 1/2	NCT04497142 Comparator	Nov 2020 → May 2023	epilepsy, malignant glioma	Dana-Farber Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT02348216 Background	Apr 2015 → Jul 2023	follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma	Kite, A Gilead Company	Completed	Met primary
Phase 2	NCT06859424 Background	Jul 2025 → Jun 2028 expected	B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3	Center for International Blood and Marrow Transplant Research	Recruiting	No outcome recorded
Phase 2	NCT06345495 Background	Oct 2024 → Jan 2027 expected	myelofibrosis, splenic disorder	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT05735717 Background	May 2023 → Nov 2027 expected	CBL-related disorder, acute lymphoblastic leukemia, acute myeloid leukemia, central nervous system leukemia +6	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT04317807 Comparator	Aug 2020 → Apr 2025	psychotic disorder	NYU Langone Health	Completed	No outcome recorded
Phase 2	NCT03436433 Comparator	Jan 2019 → Dec 2020	brain glioma	Duke University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT06625359 Background	Jun 2015 → Sep 2024	central nervous system non-hodgkin lymphoma	Seoul National University Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01857934 Background	Jul 2013 → Oct 2021	neuroblastoma	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 2	NCT01464359 Background	Oct 2011 → Oct 2013	acute myeloid leukemia	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00970814 Comparator	Oct 2009 → Aug 2010	alcohol dependence	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Completed	No outcome recorded
Phase 2	NCT00489281 Background	Jun 2008 → Dec 2018	sickle cell disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00629889 Comparator	Feb 2008 → May 2012	central nervous system neoplasm, epilepsy	Dr Andrea Rossetti	Completed	No outcome recorded
Phase 2	NCT00291733 Comparator	May 2006 → Oct 2007	drug-induced dyskinesia	1st Hospital of Social Security Services	Unknown	No outcome recorded
Phase 2	NCT01463033 Comparator	Apr 2005 → Jun 2008	post-traumatic epilepsy	Pavel Klein	Completed	No outcome recorded
Phase 2/3	NCT04172311 Comparator	Nov 2019 → Mar 2021	epilepsy	Lady Hardinge Medical College	Unknown	No outcome recorded
Phase 2/3	NCT03580707 Comparator	Jun → Dec 2018	photosensitive epilepsy	Rosenfeld, William E., M.D.	Completed	No outcome recorded
Phase 2/3	NCT00299611 Comparator	Nov 2005 → Dec 2007	obsessive-compulsive disorder	Duke University	Terminated	No outcome recorded
Phase 2/3	NCT00413296 Comparator	Nov 2005 → Sep 2007	post-traumatic stress disorder	Duke University	Completed	No outcome recorded
Phase 3	NCT06907173 Background	Mar 2026 → Jun 2029 expected	—	University of Virginia	Recruiting	No outcome recorded
Phase 3	NCT07336992 Comparator	Jan 2026 → Jul 2029 expected	intracerebral hemorrhage	Hospices Civils de Lyon	Not yet recruiting	No outcome recorded
Phase 3	NCT07490769 Comparator	Oct 2025 → Dec 2028 expected	epilepsy	Waad Alkathiri	Recruiting	No outcome recorded
Phase 3	NCT05722951 Background	Oct 2022 → Jun 2024	epilepsy	Tanta University	Completed	No outcome recorded
Phase 3	NCT01960075 Comparator	Oct 2015 → Feb 2019	—	University of Virginia	Completed	No outcome recorded
Phase 3	NCT02201251 Comparator	Oct 2014 → Apr 2020	epilepsy	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 3	NCT02726867 Comparator	Feb 2014 → Nov 2016	epilepsy	Mid-Atlantic Epilepsy and Sleep Center, LLC	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT01891890 Comparator	Aug 2013 → Oct 2015	focal epilepsy	Emory University	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01375374 Background	Jul 2011 → Mar 2013	focal epilepsy	UCB Pharma	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00563459 Comparator	Nov 2007 → Apr 2010	epilepsy	SK Life Science, Inc.	Terminated	No outcome recorded
Phase 3	NCT00537238 Comparator	Oct 2007 → May 2012	focal epilepsy	Viatris Inc.	Completed	No outcome recorded
Phase 3	NCT00758277 Comparator	May 2007 → Jul 2009	alcohol dependence	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 3	NCT00146471 Comparator	Jan 2006 → Jul 2007	alcohol withdrawal	Charite University, Berlin, Germany	Completed	No outcome recorded
Phase 3	NCT00279617 Comparator	Jan 2006 → Feb 2009	panic disorder	Lindner Center of HOPE	Completed	No outcome recorded
Phase 3	NCT00242606 Comparator	Mar 2005 → Jun 2008	epilepsy	Philipps University Marburg	Completed	No outcome recorded
Phase 4	NCT07284498 Comparator	Jan → Sep 2026 overdue	brain hypoxia - ischemia, neonatal epilepsy syndrome	Mansoura University	Not yet recruiting	No outcome recorded
Phase 4	NCT06403150 Comparator	May 2023 → Aug 2024	—	Dhaka Medical College	Completed	No outcome recorded
Phase 4	NCT04759196 Comparator	Mar 2021 → Sep 2024	epilepsy	University of Sherbrooke	Unknown	No outcome recorded
Phase 4	NCT04610879 Comparator	Aug 2019 → Sep 2020	self-limited epilepsy with centrotemporal spikes	King's College London	Terminated	No outcome recorded
Phase 4	NCT03490487 Background	Jun 2018 → Dec 2020	self-limited epilepsy with centrotemporal spikes	Assiut University	Unknown	No outcome recorded
Phase 4	NCT03048084 Comparator	Feb 2018 → Jul 2026 overdue	glioma	Leiden University Medical Center	Recruiting	No outcome recorded
Phase 4	NCT03107507 Comparator	Mar → Oct 2017	neonatal epilepsy syndrome	Cairo University	Unknown	No outcome recorded
Phase 4	NCT02670161 Comparator	May 2016 → Dec 2026 expected	Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6	Endeavor Health	Enrolling by invitation	No outcome recorded
Phase 4	NCT02205931 Comparator	Jan 2015 → Jun 2018	epilepsy	University College, London	Unknown	No outcome recorded
Phase 4	NCT01974700 Comparator	Jul 2013 → Feb 2016	brain aneurysm, epilepsy	Indiana University	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT01935908 Comparator	May 2013	epilepsy, subarachnoid hemorrhage	Vanderbilt University Medical Center	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT01801072 Comparator	Feb 2013 → Oct 2023	brain aneurysm, epilepsy	University of Michigan	Completed	No outcome recorded
Phase 4	NCT00552526 Comparator	Nov 2007 → Jan 2011	epilepsy	Oslo University Hospital	Unknown	No outcome recorded
Phase 4	NCT00618436 Comparator	Aug 2007 → Sep 2009	subarachnoid hemorrhage, traumatic brain injury	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00438451 Comparator	Jan 2007 → Jul 2010	focal epilepsy	Johannes Gutenberg University Mainz	Completed	No outcome recorded
Phase 4	NCT00252954 Comparator	Nov 2005 → Mar 2008	spinal cord injury	Danish Pain Research Center	Completed	No outcome recorded
—	NCT07098728 Comparator	Jul 2025 → Mar 2026 overdue	epilepsy	Ministry of Health and Sports, Myanmar	Recruiting	No outcome recorded
—	NCT06067412 Comparator	Aug 2022 → Jan 2023	—	Shaheed Zulfiqar Ali Bhutto Medical University	Completed	No outcome recorded
—	NCT03636958 Background	Feb 2021 → Jul 2025	epilepsy	Assistance Publique Hopitaux De Marseille	Withdrawn	No outcome recorded
—	NCT01505569 Background	Oct 2011 → Feb 2024	Ewing sarcoma, atypical teratoid rhabdoid tumor, germ cell tumor, hepatoblastoma +6	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT00774306 Comparator	Apr 2009 → Jun 2012	subarachnoid hemorrhage	Thomas Jefferson University	Terminated	No outcome recorded
—	NCT00916149 Comparator	Jan 2007 → Oct 2012	epilepsy	Massachusetts General Hospital	Completed	No outcome recorded
—	NCT00566150 Comparator	Oct 2005 → Aug 2008	bipolar depression	Yale University	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 20

Date	Issuer	Release
2026-02-17	AgeneBio	Results Recent Report That Levetiracetam Could Stop the Plaque Formation of Alzheimer’s Disease in Its Earliest Stages Is Further Confirmation of The Positive Effects of AgeneBio’s Novel Therapeutic Approach to Treating Alzheimer’s Disease agenebio.com ↗ Newly published research from Northwestern University reports that levetiracetam prevented the formation of amyloid-beta plaques in preclinical models of Alzheimer’s disease.
2024-10-17	AgeneBio	Results AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele agenebio.com ↗ The Phase 2B trial showed 40% less clinical decline and significantly reduced atrophy of the entorhinal cortex, a key marker of disease progression, compared to placebo in ApoE-4 non- carriers with MCI due to AD
2024-04-23	AgeneBio	Results AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit agenebio.com ↗ Consistent with a decrease in clinical and cognitive progression (CDR sum of boxes), brain atrophy was reduced by AGB101 compared to placebo in a 78-week double-blind randomized controlled study
2023-11-21	Halcygen Pharmaceuticals Limited	Regulatory Strides receives USFDA approval for Levetiracetam Oral Solution strides.com ↗
2021-07-08	Ache Laboratorios Farmaceuticos S.A.	Regulatory Consulta pública: dê voz a essa causa! ache.com.br ↗ Foi aberta uma Consulta Pública a respeito dos Protocolos Clínicos e Diretrizes Terapêuticas (PCDT) do tratamento da epilepsia focal e generalizada, epilepsia mioclônica juvenil resistentes à monoterapia.
2017-02-27	Addex Pharma S.A.	Results Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia addextherapeutics.com ↗
2015-11-06	AgeneBio	Results AgeneBio Presents Pharmacokinetic Profile of Proprietary, Extended-Release, Once-a-Day AGB101 Formulation at 8th Clinical Trials on Alzheimer’s Disease agenebio.com ↗ The study showed that sustained plasma levels of levetiracetam consistent with AGB101 Phase 2 efficacy were observed over a 14-hour period.
2015-09-23	Addex Pharma S.A.	Results Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy addextherapeutics.com ↗ Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that ADX71149, a metabotropic glutamate receptor type 2 (mGluR2) positive allosteric modulator (PAM), demonstrated synergistic efficacy with levetiracetam (a globally commercialized antiepileptic drug) in preclinical models of epilepsy.
2015-03-26	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory Novel Anti-epileptic Drug E Keppra Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures® otsuka.co.jp ↗ An application has now been submitted to Japan's Pharmaceutical and Medical Devices Agency for the additional indication of adjunctive therapy for generalized tonic-clonic seizures.
2015-03-11	AgeneBio	Results AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer’s Dementia agenebio.com ↗ The results show that AGB101 restored brain network function and significantly improved memory in elderly patients with aMCI.
2015-02-20	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory Novel Anti-epileptic Drug E Keppra Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures® otsuka.co.jp ↗ E Keppra recently obtained an additional indication of monotherapy, making it possible to use it to treat partial-onset seizures in all patients aged four years and over.
2014-08-04	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory E Keppra 500 mg Injectable For Monotherapy Treatment of Epilepsy Submitted For Regulatory Review in Japan® otsuka.co.jp ↗ An application for use as monotherapy has now also been submitted.
2014-07-04	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory E Keppra Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over® otsuka.co.jp ↗ Otsuka Pharmaceutical Co., Ltd. (headquarters: Tokyo; President and Representative Director: Taro Iwamoto;) and UCB Japan Co., Ltd. (headquarters: Tokyo; President and Representative Director: Joel Peterson) received marketing authorization in Japan on July 4, 2014, 2014 for E Keppra for IV Drip Infusion 500 mg (levetiracetam).
2014-03-07	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory Anti-Epileptic Drug E Keppra Filed in Japan for Additional Indication of Monotherapy for Partial-Onset Seizures® otsuka.co.jp ↗ An application for regulatory approval has been submitted in Japan for E Keppra to be used as monotherapy in addition to its current use as adjunctive therapy.
2013-06-28	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory Two New Formulations of E Keppra Developed Dry Syrup Obtains Approval; Application Filed for Injectable FormulationAddress various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medication® otsuka.co.jp ↗ received marketing authorization from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra Dry Syrup 50% on June 28.
2013-05-31	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory Antiepileptic Drug E Keppra Tablet Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)® otsuka.co.jp ↗ today obtained regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for E Keppra 250 mg and 500 mg Tablets (levetiracetam)
2012-06-21	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory UCB Japan Files for Indication of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra Tablet; New Dry Syrup Formulation Filed at the Same Time ® otsuka.co.jp ↗ The company filed for approval of a new dry syrup formulation E Keppra Dry Syrup 50% at the same time.
2010-07-23	Otsuka Pharmaceutical Development & Commercialization, Inc.	Regulatory E Keppra (levetiracetam) receives regulatory approval in Japan® otsuka.co.jp ↗ E Keppra has been approved in Japan as adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalisation, in adult patients with epilepsy, who have not obtained sufficient response to other antiepileptic drugs.
2010-06-17	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma announces USFDA approval for generic KeppraÂ® Injection, levetiracetam® injection sunpharma.com ↗ Sun Pharma announced that USFD A has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra ® Injection, levetiracetam injection.
2009-02-12	Wockhardt	Regulatory Wockhardt to launch Leveiracetam, a generic version of epilepsy drug in the US market wockhardt.com ↗ Wockhardt Limited received ap proval from the United States Food & Drug Administration (US FDA) for marketing the tablets containing 250mg, 500mg, 750mg and 1gm Levetiracetam which is used for treating various kinds of epileptic seizures.

All press releases naming this drug 28 releases

Date	Issuer	Release
2026-02-17	AgeneBio	Recent Report That Levetiracetam Could Stop the Plaque Formation of Alzheimer’s Disease in Its Earliest Stages Is Further Confirmation of The Positive Effects of AgeneBio’s Novel Therapeutic Approach to Treating Alzheimer’s Disease agenebio.com ↗
2024-10-17	AgeneBio	AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele agenebio.com ↗
2024-04-23	AgeneBio	AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit agenebio.com ↗
2023-11-21	Halcygen Pharmaceuticals Limited	Strides receives USFDA approval for Levetiracetam Oral Solution strides.com ↗
2021-07-08	Ache Laboratorios Farmaceuticos S.A.	Consulta pública: dê voz a essa causa! ache.com.br ↗
2021-04-29	AgeneBio	AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease agenebio.com ↗
2019-03-11	Otsuka Pharmaceutical Development & Commercialization, Inc.	Notice regarding the conclusion of co-development/co-promotion activities in Japan for the anti-epileptic drug "E Keppra" otsuka.co.jp ↗
2019-01-17	AgeneBio	AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease agenebio.com ↗
2017-02-27	Addex Pharma S.A.	Addex’s ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia addextherapeutics.com ↗
2016-02-29	Otsuka Pharmaceutical Development & Commercialization, Inc.	Anti-epileptic Drug E Keppra (generic name: levetiracetam) Obtains Additional Indication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan® otsuka.co.jp ↗
2015-11-26	Otsuka Pharmaceutical Development & Commercialization, Inc.	E Keppra Injectable, to be Launched in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures® otsuka.co.jp ↗
2015-11-06	AgeneBio	AgeneBio Presents Pharmacokinetic Profile of Proprietary, Extended-Release, Once-a-Day AGB101 Formulation at 8th Clinical Trials on Alzheimer’s Disease agenebio.com ↗
2015-09-23	Addex Pharma S.A.	Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy addextherapeutics.com ↗
2015-03-26	Otsuka Pharmaceutical Development & Commercialization, Inc.	Novel Anti-epileptic Drug E Keppra Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures® otsuka.co.jp ↗
2015-03-11	AgeneBio	AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer’s Dementia agenebio.com ↗
2015-02-20	Otsuka Pharmaceutical Development & Commercialization, Inc.	Novel Anti-epileptic Drug E Keppra Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures® otsuka.co.jp ↗
2014-08-04	Otsuka Pharmaceutical Development & Commercialization, Inc.	E Keppra 500 mg Injectable For Monotherapy Treatment of Epilepsy Submitted For Regulatory Review in Japan® otsuka.co.jp ↗
2014-07-04	Otsuka Pharmaceutical Development & Commercialization, Inc.	E Keppra Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over® otsuka.co.jp ↗
2014-03-07	Otsuka Pharmaceutical Development & Commercialization, Inc.	Anti-Epileptic Drug E Keppra Filed in Japan for Additional Indication of Monotherapy for Partial-Onset Seizures® otsuka.co.jp ↗
2013-08-28	Otsuka Pharmaceutical Development & Commercialization, Inc.	Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra Dry Syrup 50%, to Be Launched on August 29® otsuka.co.jp ↗
2013-06-28	Otsuka Pharmaceutical Development & Commercialization, Inc.	Two New Formulations of E Keppra Developed Dry Syrup Obtains Approval; Application Filed for Injectable FormulationAddress various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medication® otsuka.co.jp ↗
2013-05-31	Otsuka Pharmaceutical Development & Commercialization, Inc.	Antiepileptic Drug E Keppra Tablet Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)® otsuka.co.jp ↗
2012-06-21	Otsuka Pharmaceutical Development & Commercialization, Inc.	UCB Japan Files for Indication of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra Tablet; New Dry Syrup Formulation Filed at the Same Time ® otsuka.co.jp ↗
2010-09-17	Otsuka Pharmaceutical Development & Commercialization, Inc.	Antiepileptic Drug 'E Keppra Tablet' with New Mechanism of Action Released on September 17® otsuka.co.jp ↗
2010-07-23	Otsuka Pharmaceutical Development & Commercialization, Inc.	E Keppra (levetiracetam) receives regulatory approval in Japan® otsuka.co.jp ↗
2010-06-17	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces USFDA approval for generic KeppraÂ® Injection, levetiracetam® injection sunpharma.com ↗
2009-02-12	Wockhardt	Wockhardt to launch Leveiracetam, a generic version of epilepsy drug in the US market wockhardt.com ↗
2008-06-10	Otsuka Pharmaceutical Development & Commercialization, Inc.	Otsuka and UCB agreed to co-develop and co-promote Keppra and Cimzia in Japan®® otsuka.co.jp ↗

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 247 sources stand behind the page.

Field	Value	Cited text
Known as	Levetiracetam	“Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗ 223 “Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗ “AGB101 has been developed as a novel extended release formulation of low dose levetiracetam (below clinically marketed doses for epilepsy) for slowing the progression of...” NCT03461861 ↗ “Both levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa photosensitivity model of epilepsy.” PMID 32949370 ↗ Oct 2020 “Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.” PMID 19317886 ↗ Mar 2009 “Although BRV is an analog of levetiracetam (LEV), in addition to being an SV2A ligand, it also inhibits sodium channels in a voltage-dependent manner.” PMID 20887370 ↗ Sep 2010 “Drugs: carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproic acid, zonisamide” NCT05236166 ↗ “Subjects will receive busulfan seizure prophylaxis with levetiracetam, fosphenytoin, or lorazepam per institutional guidelines.” NCT06859424 ↗ “carbamazepine, valproic acid, topiramate, oxcarbazepine, levetiracetam or lamotrigine” NCT02429596 ↗ “a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)” NCT06549426 ↗ “Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously” NCT02056236 ↗ Show 213 more sources
Known as	(S)-α-ethyl-2-oxo-pyrrolidine acetamide	“Levetiracetam (LEV: (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is an anticonvulsant/antiepileptic drug.” NCT02647437 ↗
Known as	AGB101	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05986721 ↗ 4 NCT06919926 ↗ NCT05824728 ↗ NCT03461861 ↗ NCT03486938 ↗
Known as	eLVT	“studies of enteral levetiracetam (eLVT) to evaluate pharmacokinetics (PK), safety and efficacy including an open-label, randomized controlled trial (RCT) comparing eLVT to...” PMID 31672143 ↗ Nov 2019
Known as	Keppra	“Patients with partial-onset seizures seen in community-based practices were to be included in this therapeutic use study * to assess the safety and tolerability of Keppra...” NCT00643500 ↗ 18 “The Safety of Keppra as Adjunctive Therapy in Epilepsy (SKATE) study aimed to evaluate the safety and efficacy of levetiracetam (Keppra, LEV) as add-on therapy for refractory...” PMID 17681453 ↗ Aug 2007 “The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A...” NCT02208492 ↗ “BACKGROUND: Levetiracetam (Keppra) is a commonly prescribed anticonvulsant that has been shown to attenuate alcohol consumption in an open-label study of treatment-seeking,...” PMID 22367657 ↗ Apr 2012 “Pilot study to evaluate efficacy of Keppra (levetiracetam) for seizure control in patients with alcohol related seizures.” NCT00627133 ↗ “Keppra (levetiracetam) is approved by the U.S. Food and Drug Administration (FDA) to treat partial seizures in adults.” NCT00361010 ↗ “They would then be rapidly transitioned off of their current anticonvulsant and onto levetiracetam (Keppra).” NCT00181116 ↗ “KEPPRA (levetiracetam) 500 mg scored tablets will be supplied with matching placebo tablets.” NCT00221988 ↗ “Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease” NCT00584025 ↗ “Follow up Trial for Keppra (Levetiracetam) as Monotherapy” NCT00291655 ↗ “Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)” NCT00946751 ↗ Show 8 more sources
Known as	Keppra (Registered Trademark)	“Levetiracetam (Keppra® (Registered Trademark)) is the most recently approved anti-epileptic drug available” NCT00015769 ↗
Known as	Keppra, Levetiracetam	“Keppra, Levetiracetam” NCT00262262 ↗
Known as	L059	“Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method” NCT00600509 ↗
Known as	LEV	“This open-label, multicenter, randomized phase IV trial (NCT01498822) of noninferiority design compared the long-term effectiveness, safety, and tolerability of levetiracetam...” PMID 28395124 ↗ Apr 2017 34 “In a recent double-blind, placebo-controlled study, adjunctive levetiracetam (LEV) was reported to be effective and well tolerated during 5-day treatment in patients aged 1...” PMID 21095488 ↗ Oct 2010 “compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients...” PMID 27552848 ↗ Aug 2016 “The Safety of Keppra as Adjunctive Therapy in Epilepsy (SKATE) study aimed to evaluate the safety and efficacy of levetiracetam (Keppra, LEV) as add-on therapy for refractory...” PMID 17681453 ↗ Aug 2007 “To evaluate the tolerability and efficacy of levetiracetam (LEV) in newly diagnosed elderly patients (aged 60 yrs or above) with focal epilepsy compared to lamotrigine (LTG) or...” NCT00438451 ↗ “HEAD-TO-HEAD Evaluation of the Antiepileptic Drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German Multi-Centre, Doubleblind Controlled Trial in Children With Benign...” NCT00471744 ↗ “Levetiracetam (LEV) regulates neuronal synaptic exocytosis and calcium-induced neurotransmitter release and has a therapeutic effect on the excitation-inhibition balance of the...” NCT04277936 ↗ “early, preventive introduction of low-dose antiepileptic drug therapy (levetiracetam [LEV] or perampanel [PER]) in patients who have experienced middle cerebral artery (MCA) infarction” PMID 37999939 ↗ Nov 2023 “Both levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa photosensitivity model of epilepsy.” PMID 32949370 ↗ Oct 2020 “Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus.” PMID 33336359 ↗ Jan 2021 “This prospective, open-label study evaluated the efficacy and safety of adjunctive levetiracetam (LEV) in Korean adults with uncontrolled partial epilepsy.” PMID 17369059 ↗ Mar 2007 Show 24 more sources
Known as	Levetaracetam	“Lorazepam OR Levetaracetam” NCT01505569 ↗
Known as	Levetiracetam (Keppra)	“Levetiracetam (Keppra)” NCT00370838 ↗
Known as	Levetiracetam XR	“Keppra XR (Levetiracetam XR)” NCT00419393 ↗
Known as	levetriacetam	“Bulsulfan-related seizure prophylaxis was given with levetriacetam (1500mg loading on day -6, 500mg twice daily on days -5 to -3).” NCT06625359 ↗
Known as	Levetriracetam	“Drug: Levetriracetam” NCT00413296 ↗
Known as	LVT	“The investigators conducted a dose- escalation study detailed elsewhere (NCT01660672) to determine the optimal dose for use in this safety and feasibility study of enteral...” NCT01982812 ↗ 2 “The PEACH trial, a double-blind, randomised, placebo-controlled, showed that clinical and/or electrographic seizures occur in more than 40% of patients with ICH and that...” NCT07336992 ↗ “OBJECTIVE: To prospectively evaluate the neuropsychological effect of levetiracetam (LVT) in comparison with carbamazepine (CBZ) and its efficacy and tolerability as a...” PMID 25948717 ↗ May 2015
Known as	S-α-ethil-2-oxo-pyrrolidine acetamide	“Levetiracetam (S-α-ethil-2-oxo-pyrrolidine acetamide) is S-enantiomer of a pyrrolidine derivative and is unrelated to any other AED and has a unique preclinical and clinical...” NCT00542802 ↗
Known as	ucb L059	“The primary objective of this study is to evaluate the plasma and urine PK of Levetiracetam (ucb L059) and its metabolite (ucb L057)” NCT01491113 ↗
Action	Inhibit	“Levetiracetam inhibits burst firing in epileptic rat hippocampus.” NCT00324454 ↗
Modality	Other / unclassified	“A double-blind placebo-controlled clinical trial was conducted using 2 comparator anticonvulsant drugs, topiramate (300 mg/d) and levetiracetam (2000 mg/d), which does not...” PMID 25427171 ↗ Feb 2015
Route	Oral	“Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.” NCT00105040 ↗
Target	SV2A	“Brivaracetam (BRV) and levetiracetam (LEV) are antiepileptic drugs that bind synaptic vesicle glycoprotein 2A (SV2A).” PMID 30924924 ↗ Mar 2019